Eruptive xanthomas associated with olanzapine use.
BACKGROUND
Since their introduction to the US market, atypical antipsychotic drugs, such as olanzapine, have been widely prescribed for the management of psychosis and have increasingly been used in dermatologic settings for the treatment of psychogenic dermatoses. Mild hyperglycemia and hypertriglyceridemia have been documented from the use of these medications, but the range of effects on metabolism and the effects on skin are poorly characterized. OBSERVETION: We describe 3 patients who developed eruptive xanthomas, 1 of whom had relative insulin insufficiency, after starting olanzapine therapy. These cases further support the association of severe dyslipidemia with olanzapine use in selected patients.


CONCLUSIONS
With the increasing use of atypical antipsychotic agents in the dermatologic setting, the dyslipidemia that develops in association with olanzapine use emphasizes the need for periodic metabolic studies in high-risk patients.
Chang
Howard Y
HY
Department of Dermatology, Program in Epithelial Biology, Stanford University School of Medicine, Stanford, Calif. 94305, USA.
Ridky
Todd W
TW
Kimball
Alexandra B
AB
Hughes
Elizabeth
E
Oro
Anthony E
AE
D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects* / Q000627:therapeutic use; D001569:Benzodiazepines; D005260:Female; D006801:Humans; D006949:Hyperlipidemias / Q000139:chemically induced* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D000077152:Olanzapine; D010890:Pirenzepine / Q000009:adverse effects* / Q000031:analogs & derivatives* / Q000627:therapeutic use; D012559:Schizophrenia / Q000188:drug therapy / Q000473:pathology; D012871:Skin Diseases / Q000139:chemically induced* / Q000473:pathology; D014973:Xanthomatosis / Q000139:chemically induced* / Q000473:pathology
D014150:Antipsychotic Agents; D001569:Benzodiazepines; D010890:Pirenzepine; D000077152:Olanzapine